Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Biotechnology Assets's Enterprise Value is €19.62 Mil.
Biotechnology Assets's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.01 Mil. Therefore, Biotechnology Assets's EV-to-OCF for today is -1,508.92.
The historical rank and industry rank for Biotechnology Assets's EV-to-OCF or its related term are showing as below:
XMAD:BST'
s EV-to-OCF Range Over the Past 10 Years
Min: -2310.68 Med: -4.04 Max: 635.78
Current: -1485.85
During the past 13 years, the highest EV-to-OCF of Biotechnology Assets was 635.78. The lowest was -2310.68. And the median was -4.04.
XMAD:BST's EV-to-OCF is ranked better than 99.72% of 1408
companies
in the Biotechnology industry
Industry Median: -3.235
vs XMAD:BST: -1485.85
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biotechnology Assets's PE Ratio (TTM) for today is calculated as:
Biotechnology Assets's share price for today is €0.216.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biotechnology Assets's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.027.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biotechnology Assets EV-to-OCF Related Terms
Biotechnology Assets EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Biotechnology Assets's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:BST vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Biotechnology Assets's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's EV-to-OCF falls into.
Biotechnology Assets's current Enterprise Value is €19.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biotechnology Assets's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotechnology Assets (XMAD:BST) has a EV-to-OCF of -1,508.92 as of Jul. 29, 2026. According to the industry distribution chart, Biotechnology Assets ranks #4 out of 1408 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Biotechnology Assets' EV-to-OCF too high?
Biotechnology Assets' current EV-to-OCF is -1,508.92. Based on the distribution chart, Biotechnology Assets ranks #4 out of 1408 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Biotechnology Assets has a GF Score™ of 19/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biotechnology Assets ranks #4 out of 1408 companies for EV-to-OCF. This places Biotechnology Assets in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Biotechnology Assets's current EV-to-OCF is -1,508.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.29, compared to a current price of €0.22 — trading 25.5% below its estimated fair value. The current EV-to-OCF is -1,508.92. Biotechnology Assets' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current EV-to-OCF is -1,508.92 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?
Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued.
The current stock price of €0.22 is trading 25.5% below its estimated GF Value™ of €0.29.
GuruFocus considers Biotechnology Assets to be Modestly Undervalued.
Key valuation signals for XMAD:BST:
EV-to-OCF: -1,508.92
GF Value™: €0.29 vs. price of €0.22 (25.5% below fair value)
No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
19GF Score
Get the complete analysis for XMAD:BST
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:BST has been successfully added to your 
